Membrane-associated signaling in human B-lymphoma lines

Experimental Cell Research

Volumn 317, Issue 2, 2011, Pages 151-162

  Tauzin, Sebastien ^a,b   Ding, Heidrun ^a   Burdevet, Dimitri ^a   Borisch, Bettina ^a   Hoessli, Daniel C ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Kinase inhibitors; Lymphoma; Membrane associated signalosome; Proximal signaling

Indexed keywords

7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; B LYMPHOCYTE RECEPTOR; COP9 SIGNALOSOME; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE LYN; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BURKITT LYMPHOMA; CELL MEMBRANE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

HUMAN HERPESVIRUS 4;

EID: 78649481961     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.09.011     Document Type: Article

References (42)

1. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
2. Bromberg J.J. STAT proteins and oncogenesis. Clin. Invest. 2002, 109:1139-1142.
3. Osaki M., Oshimura M., Ito H. The PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
4. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
5. Gao N., Flynn D.C., Zhang Z., Zhong X.-S., Walker V., Liu K.J., Shi X., Jiang B.-H. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/m TOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. 2004, 287:C281-C291.
6. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002, 14:381-395.
7. Marone R., Cmiljanovic V., Giese B., Wymann M.P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta: Proteins Proteomics 2008, 1784:159-185.
8. Al-Alwan M.M., Okkenhaug K., Vanhaesebroeck B., Hayflick J.S., Marshall A.J. Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation. J. Immunol. 2007, 178:2328-2335.
9. Inabe K., Kurosaki T. Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood 2002, 99:584-589.
10. Stephens L.R., Anderson K.E., Hawkins P.T. Src family kinases mediate receptor-stimulated, phosphoinositide 3-kinase-dependent, tyrosine phosphorylation of dual adaptor for phosphotyrosine and 3-phosphoinositide-1 in endothelial and B cell lines. J. Biol. Chem. 2001, 276:42767-42773.
11. Ahn E., Lee H., Yun Y. LIME acts as a transmembrane adapter mediating BCR-dependent B-cell activation. Blood 2006, 107:1521-1527.
12. Cherukuri A., Cheng P.C., Pierce S.K. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 2001, 167:163-172.
13. Pierce S.K. Lipid rafts and B-cell activation. Nat. Rev. Immunol. 2002, 96-105.
14. Dal Porto J.M., Gauld S.B., Merrell K.T., Mills D., Pugh-Bernard A.E., Cambier J. B cell antigen receptor signaling 101. Mol. Immunol. 2004, 41:599-613.
15. Leseux L., Hamdi S.M., al Saati T., Capilla F., Recher C., Laurent G., Bezombes C. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006, 108:4156-4162.
16. Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., Porett G., Gaidano G., Calabrese G., Martinelli G., Baldini L., Pruneri G., Capella C., Zucca C., Cotter E., Cigudosa F.E., Cotter J.C., Cigudosa C.V., Catapano M.G., Bertoni F. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br. J. Haematol. 2006, 132:303-316.
17. Chen L., Monti S., Juszczynski P., Daley J., Chen W., Witzig T.E., Habermann T.M., Kutok J.L., Shipp M.A. Syk-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111:2230-2237.
18. Gururajan M., Jennings C.D., Bondada S. Constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J. Immunol. 2006, 176:5715-5719.
19. Tauzin S., Ding H., Khatib K., Ahmad I., Burdevet D., van Echten-Deckert G., Lindquist J.A., Schraven B., Din NU, Borisch B., Hoessli D.C. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood 2008, 111:2310-2320.
20. Brown D.A. Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiology 2006, 21:430-439.
21. Hoessli D.C., Ilangumaran S., Soltermann A., Robinson P.J., Borisch B., Nasir-ud-Din Signaling through sphingolipid microdomains of the plasma membrane; the concept of signaling platform. Glycoconj. J. 2000, 17:1-7.
22. Simons K., Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000, 1:31-39.
23. Kluin-Nelemans J., Limpens J., Meerabux J., Beverstock G., Jansen J., de Jong D., Kluin P. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia 1991, 5:221-227.
24. Semac I., Palomba C., Kulangara K., Klages N., van Echten-Deckert G., Borisch B., Hoessli D.C. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 2003, 63:534-540.
25. Uddin S., Hussain A.R., Siraj A.K., Manogaran P.S., Al-Jomah N.A., Moorji A., Atizado V., Al-Dayel F., Belgaumi A., El-Solh H., Ezzat A., Bavi P., Al-Kuraya K.S. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186.
26. Rudelius M., Pittaluga S., Nishizuka S., Pham T.H.-T., Fend F., Jaffe E.S., Quintanilla-Martinez L., Raffeld M. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
27. Shair K.H.Y., Bendt K.M., Edwards R.H., Bedford E.C., Nielsen J.N., Raab-Traub N. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog. 2007, 3:1669-1683.
28. Brdicka T., Pavlistova D., Leo A., Bruyns E., Korinek V., Angelisova P., Scherer J., Shevchenko A., Shevchenko A., Hilgert I., Cerny J., Drbal K., Kuramitsu Y., Kornacker B., Horejsi V., Schraven B. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein kinase csk and is involved in regulation of T cell function. J. Exp. Med. 2000, 191:1591-1604.
29. Arcaro A., Aubert M., Espinosa de Hierro M.E., Khanzada U.K., Angekidou S., Tetley T.D., Bittermann A.G., Frame M.C., Seckl M.J. Critical role for lipid-associated Src kinases in activation of PI3K-Akt signalling. Cell. Signal. 2007, 19:1081-1092.
30. Sirvent A., Bénistant C., Pannequin J., Veracini L., Simon V., Bourgaux J.-F., Hollande F., Cruzalegui F., Roche S. Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene 2010, 29:1303-1315.
31. Contri A., Brunati A.M., Trentin L., Cabrelle A., Miorin M., Cesaro L., Pinna L.A., Zambello R., Semenzato G., Donella-Deana A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest. 2005, 115:369-378.
32. Dos Santos C., Demur C., Bardet V., Prade-Houdellier N., Payrastre B., Recher C. A critical role for Lyn in acute myeloid leukemia. Blood 2008, 111:2269-2279.
33. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim. Biophys. Acta 2007, 1784:56-65.
34. Rickles R.R., Botfield M.C., Weng Z., Taylor J.A., Green O.M., Brugge J.S., Zoeller M.J. Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries. EMBO J. 1994, 13:5598-5604.
35. Hope H.R., Pike L.J. Phosphoinositides and phosphoinositide-utilizing enzymes in detergent-insoluble lipid domains. Mol. Biol. Cell 1996, 7:843-851.
36. van Rheenen J., Achame E., Janssen H., Calafat J., Jalink K. PIP2 signaling in lipid domains: a critical reevaluation. EMBO J. 2005, 24:1664-1673.
37. Gao X., Zhang J. Spatiotemporal analysis of differential Akt regulation in plasma membrane microdomains. Mol. Biol. Cell 2008, 10:518-528.
38. Law D.A., Nannizzi-Alaimo L., Ministri K., Hughes P.E., Forsyth J., Turner M., Shattil S.J., Ginsberg M.H., Tybulewicz V.L.J., Phillips D.R. Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets. Blood 1999, 93:2645-2652.
39. Monroe J.G. ITAM-mediated tonic signaling through pre-BCR and BCR complexes. Nat. Rev. Immunol. 2006, 6:283-294.
40. Ke J., Chelvaran Lakshman R., Sindhava V., Robertson D.A., Lekakis L., Jennings C.D., Bondada S. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Mol. Cancer 2009, 8:132-146.
41. Braselmann S., Taylor V., Zhao H., Wang S., Sylvain C., Baluom M., Qu K., Herlaar E., Lau A., Young C., Wong B.R., Lovell S., Sun T., Park G., Argade A., Jurcevic S., Pine P., Singh R., Grossbard E.B., Payan D.G., Masuda E.S. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling abd reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 2006, 319:998-1008.
42. Tsang E., Giannetti A.M., Shaw D., Dinh M., Tse J.K.Y., Gandhi S., Ho H., Wang S., Papp E., Bradshaw J.M. Molecular mechanism of the Syk activation switch. J. Biol. Chem. 2008, 283:32650-32659.